🇺🇸 FDA
Pipeline program

EDIT-301

EM-301-BThal-001

Phase 2 gene_therapy active

Quick answer

EDIT-301 for Transfusion Dependent Beta Thalassemia is a Phase 2 program (gene_therapy) at Editas Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Editas Medicine
Indication
Transfusion Dependent Beta Thalassemia
Phase
Phase 2
Modality
gene_therapy
Status
active

Clinical trials